PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

Summary

This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, nonrandomized, open label, phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma.

Timeline

Start

2014-12

Primary completion

2016-07-11

Completion

2018-08-22

Drugs

Indications